Gapping up
In reaction to strong earnings/guidance:
- CYH +20.3%, RIC +16.3%, XCRA +11.6%, HLX +8%, EXAS +7.2%, VIPS +6.9%, LL +6.1%, EROS +5.6%, OPME +3.6%
- MDR +3.3%, WMT +3.2%, CTG +3%, AAP +2.4%, MDWD +2.4%, CYRN +2.3%, NRZ +2%, M +1.9%, NDSN +1.7%, HD +1.7%, EXPD +0.9%, WLK +0.6%
M&A news:
- DGAS +16.6% (enters into a definitive agreement to merge with an affiliate of Peoples Natural Gas; Delta shareholders will receive $30.50 in cash/share)
- PLKI +16.4% (Restaurant Brands (QSR) is in advanced discussions to purchase PLKI, according to Bloomberg)
- FCH +15.8% (Ashford Hospitality Trust (AHT) submits non-binding proposal to acquire FelCor for a total consideration of $9.27 per share)
- TROX +14.4% (to acquire the TiO2 business of Cristal for $1.673 bln of cash and Class A ordinary shares)
Select metals/mining stocks trading higher: CLF +2.9%, AKS +2.5%, X +1.5%, MT +1.3%, HBM +1.2%, AUY +0.8%, .
Other news:
- DCTH +46.3% (study demonstrated that 45.7% of patients with ocular melanoma that metastasized to the liver who underwent percutaneous hepatic perfusion using investigational Melphalan/HDS experienced a complete or partial response)
- EYEG +34.1% (enters into exclusive, worldwide licensing agreement with Valeant Pharmaceuticals (VRX) )
- APOP +20.1% (announces 'positive' final results from its clinical trial of ApoGraft in healthy donors)
- IDXG +19.5% (announces the initiation of a collaborative research program with Viatar CTC Solutions to detect and characterize early cancer in liquid biopsies)
- VCEL +8.2% (FDA has designated the investigation of ixmyelocel-T for reduction in the risk of death and cardiovascular hospitalization in patients with chronic advanced heart failure due to ischemic dilated cardiomyopathy as a Fast Track Development Program)
- VALE +7.6% (new shareholders' agreement was filed, executed by Litel Participações S.A., Litela Participações S.A., Bradespar S.A., Mitsui & Co., and BNDES Participações
- RBS +5.4% (provides update on remaining State Aid obligation)
- EW +5.3% (CardiAQ testing has been completed; enrollment has resumed )
- BCLI +4.2% (signs an agreement w/ CCRM to support the market authorization request for NurOwn)
- PGH +3.1% (announcs plan to reduce its outstanding debt through the use of $530 mln cash on hand)
- MDLZ +2.6% (following confirmation that KHC withdrew transaction with UL/UN)
- GRPN +1.9% (continued strength)
- SRPT +1.8% (enters into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $125 million)
- AEHR +1.5% (receives an order in excess of $4 mln from a subcontractor to its lead customer for the FOX-XP Test and Burn-in System)
- SCON +1.4% (receives a U.S. Patent for an aspect of the RCE-CDR system architecture used in manufacturing Conductus HTS wire)
- GIS +1.3% (following confirmation that KHC withdrew transaction with UL/UN)
Analyst comments:
- JAG +3.7% (initiated with a Outperform at Credit Suisse)
- SBLK +3.1% (upgraded to Buy from Hold at Deutsche Bank)
- ADNT +1.3% (initiated with a Overweight at Morgan Stanley)